HURA

TuHURA Biosciences, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-31

Figures on this page computed 2026-11-08 12:40 UTC

Last close

1.72USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-31

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-134950
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-31
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-134950
Reported in
USD
- 10-K for 2025, filed 2026-03-31
- 10-K for 2025, filed 2026-03-31
- 10-K for 2025, filed 2026-03-31
- 10-Q for 2025, filed 2026-08-14
- 10-K for 2025, filed 2026-03-31
- 10-Q for 2025, filed 2026-08-14
The filing itself
n/aNet margin
We do not hold this figure for this company, so there is nothing to place.
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-134950
Reported in
USD
- 10-K for 2025, filed 2026-03-31
- 10-K for 2025, filed 2026-03-31
The filing itself
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-134950
Reported in
USD
- 10-K for 2025, filed 2026-03-31
- 10-K for 2025, filed 2026-03-31
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-134950
Reported in
USD
- 10-K for 2025, filed 2026-03-31
- 10-Q for 2025, filed 2026-08-14
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Safety is the furthest below its sector's middle: 0.13 against 0.72 on the market's range.

Margins: n/aWe do not hold this figure for this company, so there is nothing to place.
What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

n/a

2.29x

1.47x

n/a

0.01x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

3 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-31

Salesn/a
Its own average over 3 years, 0.
Profit2.29x
Its own average over 10 years, -13.1M.
Free cash flow1.47x
Its own average over 5 years, -18.8M.
Debtn/a
Its own average over 3 years, 252.0K.
Price0.01x
Its own average over 11 years, 241. Market data, 2026-11-04

Profit is furthest from its own average, at 2.29 times.

Profit is 2.29 times its own 10-year average; Free cash flow is 1.47 times its own 5-year average; Price is 0.01 times its own 11-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-31

Sales against its own 3-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-134950
Reported in
USD
The filing itself
Profit against its own 10-year average2.29
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-134950
Reported in
USD
The filing itself
Free cash flow against its own 5-year average1.47
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-134950
Reported in
USD
The filing itself
Debt against its own 3-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-134950
Reported in
USD
The filing itself
Price against its own 11-year average0.01Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD